Presentation of Andrew Chalmers in 1st International Antibody Validation Forum 2014
•Download as PPTX, PDF•
1 like•1,596 views
Dr Chalmers is a cell biologist based at the University of Bath, UK and he currently leads a team investigating the role of stem cell regulators in prostate cancer. In 2014 he was promoted to a Senior Lectureship. Dr Chalmers have published over 25 peer reviewed papers, been invited to national and international conferences and been awarded major research grants from research councils and charities. He is also the founder of CiteAb, a citation based antibody search engine. The idea of CiteAb was birthed through frustration with using failed commercial antibodies. CiteAb aims to provide a better way for researchers to find antibodies which are suitable for their experiments. CiteAb was spun out of the University of Bath in January 2014 and Dr Chalmers is the currently the Chief Scientific Officer. For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blog
Report
Share
Report
Share
Recommended
Presentation of John Mountzouris in 1st International Antibody Validation For...
Presentation of John Mountzouris in 1st International Antibody Validation For...St John's Laboratory Ltd
John Mountzouris completed his Ph.D. in Medicinal Chemistry at the University of Texas, with a focus on structural biology, followed by a post-doctorate at the Scripps Research Institute. His industrial career begin with a stint as a bench scientist Pharmingen (later acquired by Becton Dickinson). He then turned to the business side, with work in sales and marketing, business development and communication at Pfizer, Abgent, and Acris Antibodies. Most recently, he has returned as Site Leader at Abgent, following its acquisition by Wuxi, a global CRO company.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogPresentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
Dr. David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. Dr. Rimm is the Director of Translational Pathology and the Director of Yale Pathology Tissue Services. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast and lung cancer and predicting recurrence or metastasis in breast and lung cancer. The technology has also been used in a series of efforts related to biospecimen science. He also has a group working on primary tumor culture using the conditionally reprogrammed cell method. He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH. He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP). He is currently supported by grants from both public and private sources. He is an author of over 280 peer-reviewed papers and 8 patents. He has served on advisory boards for Genentech, Novaritis, BMS, Perkin Elmer, Dako, ACD, Avida and Genoptix. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogPresentation of Frank Hills in 1st International Antibody Validation Forum 2014
Presentation of Frank Hills in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
After graduating with an honours degree in Biochemistry Dr Hills worked for several years as a Clinical Scientist at St Bartholomew's hospital in London. He was awarded his PhD in 2002 from the faculty of Medicine at Queen Mary University of London. He continued his interest in reproductive science at Imperial College London where he worked as a postdoctoral researcher before joining Middlesex in 2004 as a lecturer. Dr Hills has published many high profile original research articles on various aspects of obstetric pathology including pre-eclampsia, recurrent miscarriage, preterm labour and fetal distress as well as several articles in the area of assisted reproduction. Currently, he is research interests include investigating the role of glycosaminoglycans and proteoglycans on the development of placental pathology and breast cancer. Dr Hills teaches a range of topics in biomedical science including clinical biochemistry, cellular and developmental biology as well as statistical analysis. He is author of around 30 peer-reviewed scientific articles and has refereed manuscripts for a variety of journals in the area of reproduction and endocrinology.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogBasics of Immunohistochemistry
This is a presentation I prepared to demonstrate my mastery of the basics of Immunohistochemistry during my first two months of employment as a Biologist at the Cell Marque Corporation. Please note, there are a few slides that appear to be dysfunctional and overlapping; this is due to the fact that these particular slides included complex animations that I designed to illustrate various scientific concepts related to the practice of Immunohistochemistry. If you wish to view this presentation in its entirety (animations included), feel free to contact me via LinkedIn and I will gladly provide you with a fully-functional version.
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...
This document discusses the development of immunohistochemistry (IHC) reference standards using genetically defined cell lines to improve standardization and quality control in IHC laboratories. The reference standards consist of cell line cores containing positively and negatively expressing proteins mounted on the same slide. The cell lines are extensively characterized and shown to produce consistent staining results across laboratories and detection methods. Using quantitative digital pathology, the reference standards allow laboratories to routinely monitor assay performance and identify variability in their IHC workflows.
Immunohistochemistry
Follow Atifa Ambreen:
Youtube: https://www.youtube.com/channel/UCVTn-4KeMtXKy1h3_9JbVmw
Facebook: https://www.facebook.com/atifaambreen786/
Instagram: https://www.instagram.com/atifa.ambreen/
https://www.instagram.com/invites/contact/?i=1qo1my1nb2qfx&utm_content=kbo8bi7
Snapchat: https://www.snapchat.com/add/atifa.ambreen
Twitter: https://twitter.com/atifa_ambreen
SUBSCRIBE ...
.
Email for inquiries: atifa.ambreen@gmail.com
Monoclonal antibody
This document provides information about monoclonal antibodies including their production, types, and applications. It discusses how monoclonal antibodies are produced using the hybridoma technique which fuses antibody producing B cells with myeloma cells. This results in immortal cell lines that produce identical antibodies targeting a single epitope. The document contrasts monoclonal and polyclonal antibodies and describes the evolution of monoclonal antibodies from murine to humanized and human forms to reduce immunogenicity. It also covers monoclonal antibody nomenclature, pharmacokinetics, adverse effects, and therapeutic uses.
Monoclonal Antibody
Antibody screening is more helpful in identifying the
highly productive cells and is more significant in the
form of laboratory techniques. Complete solution on screening
of antibodies can be effectively offered only
by such kinds of reputed medical institutions.
For more details please visit
http://www.axiomxinc.com/
Recommended
Presentation of John Mountzouris in 1st International Antibody Validation For...
Presentation of John Mountzouris in 1st International Antibody Validation For...St John's Laboratory Ltd
John Mountzouris completed his Ph.D. in Medicinal Chemistry at the University of Texas, with a focus on structural biology, followed by a post-doctorate at the Scripps Research Institute. His industrial career begin with a stint as a bench scientist Pharmingen (later acquired by Becton Dickinson). He then turned to the business side, with work in sales and marketing, business development and communication at Pfizer, Abgent, and Acris Antibodies. Most recently, he has returned as Site Leader at Abgent, following its acquisition by Wuxi, a global CRO company.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogPresentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
Dr. David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. Dr. Rimm is the Director of Translational Pathology and the Director of Yale Pathology Tissue Services. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast and lung cancer and predicting recurrence or metastasis in breast and lung cancer. The technology has also been used in a series of efforts related to biospecimen science. He also has a group working on primary tumor culture using the conditionally reprogrammed cell method. He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH. He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP). He is currently supported by grants from both public and private sources. He is an author of over 280 peer-reviewed papers and 8 patents. He has served on advisory boards for Genentech, Novaritis, BMS, Perkin Elmer, Dako, ACD, Avida and Genoptix. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogPresentation of Frank Hills in 1st International Antibody Validation Forum 2014
Presentation of Frank Hills in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
After graduating with an honours degree in Biochemistry Dr Hills worked for several years as a Clinical Scientist at St Bartholomew's hospital in London. He was awarded his PhD in 2002 from the faculty of Medicine at Queen Mary University of London. He continued his interest in reproductive science at Imperial College London where he worked as a postdoctoral researcher before joining Middlesex in 2004 as a lecturer. Dr Hills has published many high profile original research articles on various aspects of obstetric pathology including pre-eclampsia, recurrent miscarriage, preterm labour and fetal distress as well as several articles in the area of assisted reproduction. Currently, he is research interests include investigating the role of glycosaminoglycans and proteoglycans on the development of placental pathology and breast cancer. Dr Hills teaches a range of topics in biomedical science including clinical biochemistry, cellular and developmental biology as well as statistical analysis. He is author of around 30 peer-reviewed scientific articles and has refereed manuscripts for a variety of journals in the area of reproduction and endocrinology.
For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blogBasics of Immunohistochemistry
This is a presentation I prepared to demonstrate my mastery of the basics of Immunohistochemistry during my first two months of employment as a Biologist at the Cell Marque Corporation. Please note, there are a few slides that appear to be dysfunctional and overlapping; this is due to the fact that these particular slides included complex animations that I designed to illustrate various scientific concepts related to the practice of Immunohistochemistry. If you wish to view this presentation in its entirety (animations included), feel free to contact me via LinkedIn and I will gladly provide you with a fully-functional version.
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...
This document discusses the development of immunohistochemistry (IHC) reference standards using genetically defined cell lines to improve standardization and quality control in IHC laboratories. The reference standards consist of cell line cores containing positively and negatively expressing proteins mounted on the same slide. The cell lines are extensively characterized and shown to produce consistent staining results across laboratories and detection methods. Using quantitative digital pathology, the reference standards allow laboratories to routinely monitor assay performance and identify variability in their IHC workflows.
Immunohistochemistry
Follow Atifa Ambreen:
Youtube: https://www.youtube.com/channel/UCVTn-4KeMtXKy1h3_9JbVmw
Facebook: https://www.facebook.com/atifaambreen786/
Instagram: https://www.instagram.com/atifa.ambreen/
https://www.instagram.com/invites/contact/?i=1qo1my1nb2qfx&utm_content=kbo8bi7
Snapchat: https://www.snapchat.com/add/atifa.ambreen
Twitter: https://twitter.com/atifa_ambreen
SUBSCRIBE ...
.
Email for inquiries: atifa.ambreen@gmail.com
Monoclonal antibody
This document provides information about monoclonal antibodies including their production, types, and applications. It discusses how monoclonal antibodies are produced using the hybridoma technique which fuses antibody producing B cells with myeloma cells. This results in immortal cell lines that produce identical antibodies targeting a single epitope. The document contrasts monoclonal and polyclonal antibodies and describes the evolution of monoclonal antibodies from murine to humanized and human forms to reduce immunogenicity. It also covers monoclonal antibody nomenclature, pharmacokinetics, adverse effects, and therapeutic uses.
Monoclonal Antibody
Antibody screening is more helpful in identifying the
highly productive cells and is more significant in the
form of laboratory techniques. Complete solution on screening
of antibodies can be effectively offered only
by such kinds of reputed medical institutions.
For more details please visit
http://www.axiomxinc.com/
Immunohistochemistry
This document summarizes immunohistochemistry (IHC) techniques. IHC combines immunological and histological methods to identify specific proteins in tissues using antigen-antibody reactions. The document discusses common IHC methods like direct, indirect, and enzyme-linked methods. It also covers important considerations for IHC like antibody selection, tissue fixation and processing, antigen retrieval, blocking, and controls. The goal of IHC is to visualize the distribution and localization of cellular components, but the quality of results depends highly on proper sample preparation.
Basics of Immunohistochemistry (IHC)
Immunohistochemistry (IHC) is a highly sensitive method that allows the localization of antigen within a cell or a tissue with high resolution. The method is based on the use of a primary antibody that specifically binds to its complementary antigen. The bound antibody may then be visualized by a variety of methods such as colorimetric end points.
Scientific Validity of Replacements for Animal-Derived Antibodies
Summary of the recommendations by the EURL-ECVAM Scientific Advisory Committee (ESAC) on the Scientific Validity of Replacements for Animal-Derived Antibodies. Presented at the ICCVAM Communities of Practice Webinar 2020, "Use of Animal-free Affinity Reagents", January 2020.
Immunohistochemical (IHC)
Immunohistochemistry (IHC) is a technique that uses antibodies to identify and visualize antigens in cells and tissues. It allows the spatial localization of proteins in intact tissue. The IHC process involves binding a primary antibody to a specific antigen, followed by a secondary antibody linked to an enzyme. When a chromogenic substrate is added, it produces a colored precipitate that marks the location of the antigen. IHC has important applications in disease diagnosis and drug development by identifying cell types and biomarkers in situ. For example, IHC can be used to diagnose breast cancer and determine tumor grade by detecting markers in biopsy tissue samples.
Human monoclonal antibody development
The document describes a proprietary method from Bioworld Consulting Laboratories for generating human antibodies. It captures and immortalizes natural human antibody producing cells to produce antigen-specific human antibodies in vitro. This avoids losing antigen-specific B-cells associated with other methods. It produces natural human antibodies characterized without recombinant technology. Within 6-8 weeks it can obtain monoclonal antibody producing clones, compared to years for traditional methods.
Basics of IHC (JRL)
This is a presentation I prepared to demonstrate my mastery of the basics of Immunohistochemistry during my first two months of employment as a Biologist at the Cell Marque Corporation. Please note, there are a few slides that appear to be dysfunctional and overlapping; this is due to the fact that these particular slides included complex animations that I designed to illustrate various scientific concepts related to the practice of Immunohistochemistry. If you wish to view this presentation in its entirety (animations included), feel free to contact me via LinkedIn and I will gladly provide you with a fully-functional version.
An Introduction to Immunohistochemistry
Immunohistochemistry (IHC) is a technique that combines immunology and histology to detect antigens in tissues using antibodies, with the main steps including preparing tissue sections, using primary and secondary antibodies to target antigens, developing signals using reporters and counterstains, and observing under a microscope. IHC is widely used for disease diagnosis by identifying molecular markers characteristic of cellular events involved in diseases like cancer and neurological disorders. Troubleshooting for IHC focuses on reducing background staining and improving antigen detection through optimizing antibody concentrations and incubation times.
Viral diagnostics for animal diseases
This document discusses various diagnostic techniques for viral animal diseases. It describes direct detection methods like electron microscopy, histopathology, and fluorescent antibody techniques. It also covers indirect detection methods like ELISA, immunochromatography, latex agglutination, and viral antibody detection techniques like complement fixation, haemagglutination inhibition, and virus neutralization tests. Emerging techniques discussed include PCR, microarrays, and nanobiosensor-based diagnostics.
priciples and applications Immunohistochemistry
This document provides an overview of immunohistochemistry (IHC), including the principle, general protocol, and key steps. IHC combines histology and immunology to identify specific tissue components using antigen-antibody reactions tagged with visible labels. The protocol involves fixing, embedding, sectioning tissues, performing antigen retrieval, incubating with primary/secondary antibodies, and visualizing the antigen-antibody complex through detection systems like peroxidase or fluorescence. Proper controls and interpretation by a pathologist are needed for accurate results.
Antibody validation
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
monoclonal antibody production & hybridization and charecterization
monoclonal antibody production hybridization and charecterization
hybridoma screening, priming, methods of antibody charecterization
Monoclonal antibodies
- Georges Köhler and Cesar Milstein developed hybridoma technology in 1975 for which they received the Nobel Prize in 1984. Hybridoma technology involves fusing myeloma cells with antibody-producing immune cells to create immortal cell lines that produce monoclonal antibodies.
- Monoclonal antibodies are identical antibodies produced by a single clone and recognize a specific antigen, whereas polyclonal antibodies are derived from different cell lines.
- Hybridoma technology involves immunizing an animal, fusing its immune cells with myeloma cells, selecting and cloning hybridoma cells that produce the desired antibody, and characterizing and storing the monoclonal antibody produced. Monoclonal antibodies have important applications in diagnostics and treatment of diseases like cancer.
1378968135.74359 immunohistochemistry
Immunohistochemistry utilizes labeled antibodies to localize specific antigens within cells and tissues. It combines histological, immunological, and biochemical techniques to visualize the distribution of cellular components through antigen-antibody reactions tagged with visible labels. Tissues are prepared through fixation and sectioning, then exposed to labeled antibodies targeting specific antigens. This allows visualization of targeted proteins and structures under a microscope. IHC is a sensitive technique useful for cancer diagnosis, differential diagnosis, and research applications.
Immunohistochemistry
This document summarizes immunohistochemistry (IHC) techniques. IHC combines immunological and histological methods to identify specific proteins in tissues using antigen-antibody reactions. The document discusses common IHC methods like direct, indirect, and enzyme-linked techniques. It also covers important considerations for IHC like antibody selection, tissue fixation and processing, antigen retrieval, blocking, and controls. The goal of IHC is to visualize the distribution and localization of cellular components, but the quality of results depends highly on proper sample preparation.
Immunohistochemistry (IHC)
Immunohistochemistry (IHC) is a technique that uses antibodies to detect specific antigens in cells and tissues. It allows visualization of the distribution and localization of antigens through staining. IHC is commonly used to diagnose diseases like cancer by identifying abnormal protein expression. It has various applications in neuroscience, pathology, and biological research to map the distribution of molecules and study cellular processes.
Immunohistochemistry METHODS
This document provides an overview of immunohistochemistry methods. It defines key terms like antigens, antibodies, affinity, and sensitivity. It discusses the history of immunohistochemistry from the 1930s to current techniques. The principles of immunohistochemistry are described, including production of primary reagents, tissue fixation, antigen retrieval, staining, and limitations. Various immunohistochemistry methods are summarized such as direct, indirect, polymer, peroxidase-antiperoxidase, and alkaline phosphatase techniques.
Immunohistochemistry in pathology laboratory
Immunohistochemistry (IHC) utilizes labeled antibodies to localize specific antigens in tissue sections through antigen-antibody interactions visualized by markers like fluorescent dyes or enzymes. IHC allows visualization of the distribution and localization of cellular components within tissues. The process involves raising antibodies to target antigens, labeling the antibodies, and applying them to tissue sections using techniques like direct, indirect, or peroxidase anti-peroxidase (PAP) methods. IHC is a sensitive and specific technique that is useful for cancer diagnosis and research applications.
Monoclonal antibody, history, development and progress
Monoclonal antibodies (mAbs) are artificially produced antibodies that are all identical and recognize the same epitope. This document summarizes the history and production of mAbs, from early discoveries in the late 19th century to modern techniques. It describes the key breakthrough of hybridoma technology by Köhler and Milstein in 1975 that allowed mass production of mAbs by fusing antibody-producing cells with myeloma cells. Various approaches to mAb production are also summarized, including recombinant techniques, phage display, plantibodies, bacterial display, and yeast display. The document concludes with discussion of applications, clinical trials, and future innovations using mAb technology.
Monoclonal antibodies
Monoclonal antibodies are antibodies that are directed against a specific antigen. They are produced by a single clone of cells and can be obtained from immortalized B-lymphocytes or recombinant cell lines. The production of monoclonal antibodies involves immunizing an animal, fusing its spleen cells with myeloma cells to form hybridomas, selecting hybridomas that secrete the desired antibody, and propagating these cells to produce large amounts of monoclonal antibodies. Monoclonal antibodies have various applications in cancer therapy, organ transplantation, disease diagnosis, and protein purification. Recent developments include FDA approvals of monoclonal antibodies for treating cancer and blood disorders.
Ab Optimization & Validation
This document provides guidance on optimizing and validating antibodies for immunohistochemistry in formalin-fixed paraffin-embedded tissues. It discusses preparing for antibody validation including obtaining product information, references, and tissues. It also covers testing different heat induced epitope retrieval solutions, pretreatments like protease digestion, antibody dilutions, detection systems, verification of results, and documentation needed for full validation. Proper validation involving pathologists is emphasized to ensure confidence in test performance and results.
El.slide stadley
The document summarizes the work of Daron Standley's lab in developing computational methods for high-throughput antibody modeling and analysis. It discusses: [1] How the lab got interested in antibodies after performing well in a modeling contest; [2] Provides background on antibody structure and generation; [3] Introduces the lab's software for fast and accurate antibody structure prediction; [4] Describes their method for clustering antibodies by predicted epitope specificity; and [5] Overviews their antibody-antigen docking approach using only sequence information.
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
The disease area that has received the most attention, time, and financial support during the last two years has been COVID-19. There has been tremendous emphasis on addressing the new challenges presented during this global pandemic, including rapid vaccine development, effective patient treatments, supplying reliable testing methods, and providing equitable healthcare access for diverse populations. Participate to learn about innovations that have been recently developed for the fight against SARS-CoV-2.
Dr. Hayley Crawford describes Integral Molecular’s catalog of 70+ SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotypedviruses) that enable researchers to rapidly test neutralization by antibodies and sera in a safe BSL-2 environment. The presentation covers Integral Molecular’s RVP offerings that include Omicron subvariants BA.1 and BA.2,and neutralizing antibody controls. Dr. Crawford also describes additional research solutions from Integral Molecular such as epitope mapping and antibody specificity profiling and how these tools together meet the most recent FDA recommendations for variant testing of vaccines and therapeutic antibodies.
Dr. Carl Marci explores the pandemic from a different viewpoint. As has becoming increasingly clear, the effects of isolation at various stages of the COVID-19 pandemic have resulted in increased stress and anxiety in numerous populations. Using real-world data, Dr. Marci explains how real-world trends and diagnoses rates of anxiety and depression can be used to understand mental health before and after the beginning of the pandemic. Dr. Marci also highlights how real-world data can be used to understand mental health trends and patient outcomes.
More Related Content
What's hot
Immunohistochemistry
This document summarizes immunohistochemistry (IHC) techniques. IHC combines immunological and histological methods to identify specific proteins in tissues using antigen-antibody reactions. The document discusses common IHC methods like direct, indirect, and enzyme-linked methods. It also covers important considerations for IHC like antibody selection, tissue fixation and processing, antigen retrieval, blocking, and controls. The goal of IHC is to visualize the distribution and localization of cellular components, but the quality of results depends highly on proper sample preparation.
Basics of Immunohistochemistry (IHC)
Immunohistochemistry (IHC) is a highly sensitive method that allows the localization of antigen within a cell or a tissue with high resolution. The method is based on the use of a primary antibody that specifically binds to its complementary antigen. The bound antibody may then be visualized by a variety of methods such as colorimetric end points.
Scientific Validity of Replacements for Animal-Derived Antibodies
Summary of the recommendations by the EURL-ECVAM Scientific Advisory Committee (ESAC) on the Scientific Validity of Replacements for Animal-Derived Antibodies. Presented at the ICCVAM Communities of Practice Webinar 2020, "Use of Animal-free Affinity Reagents", January 2020.
Immunohistochemical (IHC)
Immunohistochemistry (IHC) is a technique that uses antibodies to identify and visualize antigens in cells and tissues. It allows the spatial localization of proteins in intact tissue. The IHC process involves binding a primary antibody to a specific antigen, followed by a secondary antibody linked to an enzyme. When a chromogenic substrate is added, it produces a colored precipitate that marks the location of the antigen. IHC has important applications in disease diagnosis and drug development by identifying cell types and biomarkers in situ. For example, IHC can be used to diagnose breast cancer and determine tumor grade by detecting markers in biopsy tissue samples.
Human monoclonal antibody development
The document describes a proprietary method from Bioworld Consulting Laboratories for generating human antibodies. It captures and immortalizes natural human antibody producing cells to produce antigen-specific human antibodies in vitro. This avoids losing antigen-specific B-cells associated with other methods. It produces natural human antibodies characterized without recombinant technology. Within 6-8 weeks it can obtain monoclonal antibody producing clones, compared to years for traditional methods.
Basics of IHC (JRL)
This is a presentation I prepared to demonstrate my mastery of the basics of Immunohistochemistry during my first two months of employment as a Biologist at the Cell Marque Corporation. Please note, there are a few slides that appear to be dysfunctional and overlapping; this is due to the fact that these particular slides included complex animations that I designed to illustrate various scientific concepts related to the practice of Immunohistochemistry. If you wish to view this presentation in its entirety (animations included), feel free to contact me via LinkedIn and I will gladly provide you with a fully-functional version.
An Introduction to Immunohistochemistry
Immunohistochemistry (IHC) is a technique that combines immunology and histology to detect antigens in tissues using antibodies, with the main steps including preparing tissue sections, using primary and secondary antibodies to target antigens, developing signals using reporters and counterstains, and observing under a microscope. IHC is widely used for disease diagnosis by identifying molecular markers characteristic of cellular events involved in diseases like cancer and neurological disorders. Troubleshooting for IHC focuses on reducing background staining and improving antigen detection through optimizing antibody concentrations and incubation times.
Viral diagnostics for animal diseases
This document discusses various diagnostic techniques for viral animal diseases. It describes direct detection methods like electron microscopy, histopathology, and fluorescent antibody techniques. It also covers indirect detection methods like ELISA, immunochromatography, latex agglutination, and viral antibody detection techniques like complement fixation, haemagglutination inhibition, and virus neutralization tests. Emerging techniques discussed include PCR, microarrays, and nanobiosensor-based diagnostics.
priciples and applications Immunohistochemistry
This document provides an overview of immunohistochemistry (IHC), including the principle, general protocol, and key steps. IHC combines histology and immunology to identify specific tissue components using antigen-antibody reactions tagged with visible labels. The protocol involves fixing, embedding, sectioning tissues, performing antigen retrieval, incubating with primary/secondary antibodies, and visualizing the antigen-antibody complex through detection systems like peroxidase or fluorescence. Proper controls and interpretation by a pathologist are needed for accurate results.
Antibody validation
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
monoclonal antibody production & hybridization and charecterization
monoclonal antibody production hybridization and charecterization
hybridoma screening, priming, methods of antibody charecterization
Monoclonal antibodies
- Georges Köhler and Cesar Milstein developed hybridoma technology in 1975 for which they received the Nobel Prize in 1984. Hybridoma technology involves fusing myeloma cells with antibody-producing immune cells to create immortal cell lines that produce monoclonal antibodies.
- Monoclonal antibodies are identical antibodies produced by a single clone and recognize a specific antigen, whereas polyclonal antibodies are derived from different cell lines.
- Hybridoma technology involves immunizing an animal, fusing its immune cells with myeloma cells, selecting and cloning hybridoma cells that produce the desired antibody, and characterizing and storing the monoclonal antibody produced. Monoclonal antibodies have important applications in diagnostics and treatment of diseases like cancer.
1378968135.74359 immunohistochemistry
Immunohistochemistry utilizes labeled antibodies to localize specific antigens within cells and tissues. It combines histological, immunological, and biochemical techniques to visualize the distribution of cellular components through antigen-antibody reactions tagged with visible labels. Tissues are prepared through fixation and sectioning, then exposed to labeled antibodies targeting specific antigens. This allows visualization of targeted proteins and structures under a microscope. IHC is a sensitive technique useful for cancer diagnosis, differential diagnosis, and research applications.
Immunohistochemistry
This document summarizes immunohistochemistry (IHC) techniques. IHC combines immunological and histological methods to identify specific proteins in tissues using antigen-antibody reactions. The document discusses common IHC methods like direct, indirect, and enzyme-linked techniques. It also covers important considerations for IHC like antibody selection, tissue fixation and processing, antigen retrieval, blocking, and controls. The goal of IHC is to visualize the distribution and localization of cellular components, but the quality of results depends highly on proper sample preparation.
Immunohistochemistry (IHC)
Immunohistochemistry (IHC) is a technique that uses antibodies to detect specific antigens in cells and tissues. It allows visualization of the distribution and localization of antigens through staining. IHC is commonly used to diagnose diseases like cancer by identifying abnormal protein expression. It has various applications in neuroscience, pathology, and biological research to map the distribution of molecules and study cellular processes.
Immunohistochemistry METHODS
This document provides an overview of immunohistochemistry methods. It defines key terms like antigens, antibodies, affinity, and sensitivity. It discusses the history of immunohistochemistry from the 1930s to current techniques. The principles of immunohistochemistry are described, including production of primary reagents, tissue fixation, antigen retrieval, staining, and limitations. Various immunohistochemistry methods are summarized such as direct, indirect, polymer, peroxidase-antiperoxidase, and alkaline phosphatase techniques.
Immunohistochemistry in pathology laboratory
Immunohistochemistry (IHC) utilizes labeled antibodies to localize specific antigens in tissue sections through antigen-antibody interactions visualized by markers like fluorescent dyes or enzymes. IHC allows visualization of the distribution and localization of cellular components within tissues. The process involves raising antibodies to target antigens, labeling the antibodies, and applying them to tissue sections using techniques like direct, indirect, or peroxidase anti-peroxidase (PAP) methods. IHC is a sensitive and specific technique that is useful for cancer diagnosis and research applications.
Monoclonal antibody, history, development and progress
Monoclonal antibodies (mAbs) are artificially produced antibodies that are all identical and recognize the same epitope. This document summarizes the history and production of mAbs, from early discoveries in the late 19th century to modern techniques. It describes the key breakthrough of hybridoma technology by Köhler and Milstein in 1975 that allowed mass production of mAbs by fusing antibody-producing cells with myeloma cells. Various approaches to mAb production are also summarized, including recombinant techniques, phage display, plantibodies, bacterial display, and yeast display. The document concludes with discussion of applications, clinical trials, and future innovations using mAb technology.
Monoclonal antibodies
Monoclonal antibodies are antibodies that are directed against a specific antigen. They are produced by a single clone of cells and can be obtained from immortalized B-lymphocytes or recombinant cell lines. The production of monoclonal antibodies involves immunizing an animal, fusing its spleen cells with myeloma cells to form hybridomas, selecting hybridomas that secrete the desired antibody, and propagating these cells to produce large amounts of monoclonal antibodies. Monoclonal antibodies have various applications in cancer therapy, organ transplantation, disease diagnosis, and protein purification. Recent developments include FDA approvals of monoclonal antibodies for treating cancer and blood disorders.
Ab Optimization & Validation
This document provides guidance on optimizing and validating antibodies for immunohistochemistry in formalin-fixed paraffin-embedded tissues. It discusses preparing for antibody validation including obtaining product information, references, and tissues. It also covers testing different heat induced epitope retrieval solutions, pretreatments like protease digestion, antibody dilutions, detection systems, verification of results, and documentation needed for full validation. Proper validation involving pathologists is emphasized to ensure confidence in test performance and results.
What's hot (20)
Scientific Validity of Replacements for Animal-Derived Antibodies
Scientific Validity of Replacements for Animal-Derived Antibodies
monoclonal antibody production & hybridization and charecterization
monoclonal antibody production & hybridization and charecterization
Monoclonal antibody, history, development and progress
Monoclonal antibody, history, development and progress
Similar to Presentation of Andrew Chalmers in 1st International Antibody Validation Forum 2014
El.slide stadley
The document summarizes the work of Daron Standley's lab in developing computational methods for high-throughput antibody modeling and analysis. It discusses: [1] How the lab got interested in antibodies after performing well in a modeling contest; [2] Provides background on antibody structure and generation; [3] Introduces the lab's software for fast and accurate antibody structure prediction; [4] Describes their method for clustering antibodies by predicted epitope specificity; and [5] Overviews their antibody-antigen docking approach using only sequence information.
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
The disease area that has received the most attention, time, and financial support during the last two years has been COVID-19. There has been tremendous emphasis on addressing the new challenges presented during this global pandemic, including rapid vaccine development, effective patient treatments, supplying reliable testing methods, and providing equitable healthcare access for diverse populations. Participate to learn about innovations that have been recently developed for the fight against SARS-CoV-2.
Dr. Hayley Crawford describes Integral Molecular’s catalog of 70+ SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotypedviruses) that enable researchers to rapidly test neutralization by antibodies and sera in a safe BSL-2 environment. The presentation covers Integral Molecular’s RVP offerings that include Omicron subvariants BA.1 and BA.2,and neutralizing antibody controls. Dr. Crawford also describes additional research solutions from Integral Molecular such as epitope mapping and antibody specificity profiling and how these tools together meet the most recent FDA recommendations for variant testing of vaccines and therapeutic antibodies.
Dr. Carl Marci explores the pandemic from a different viewpoint. As has becoming increasingly clear, the effects of isolation at various stages of the COVID-19 pandemic have resulted in increased stress and anxiety in numerous populations. Using real-world data, Dr. Marci explains how real-world trends and diagnoses rates of anxiety and depression can be used to understand mental health before and after the beginning of the pandemic. Dr. Marci also highlights how real-world data can be used to understand mental health trends and patient outcomes.
Antibody Discovery by Single B Cell Screening on Beacon®
Amy Sheng, PhD provides an overview of antibody screening platforms and presents applications and case studies using the Beacon® platform for antibody discovery.
Single B cell screening is a powerful and efficient strategy for generating antigen-specific monoclonal antibodies. Distinguished with fluorescence-activated B cell sorting, the Beacon® platform is based on plasma cell screening, making it easier to obtain antibody genes.
The Beacon® single-cell optofluidic system combines a unique optoelectro positioning (OEP) technology with novel microfluidic technology. It can be used to accurately select single cells on a chip, perform multiple single-cell assays, and export target cells based on specific results. The Beacon® optofluidic platform preserves the diversity of B cells, generating high-quality positive hits at an early stage of discovery and avoiding the loss of “good clones”.
Key Topics Include:
- B cell differentiation and development
- Pros and cons of mainstream antibody screening platforms
- Mechanisms, applications, and case studies using the Beacon® platform for antibody screening
- Sino Biological’s capacity using the Beacon® platform
PEGS China 2015 Final Agenda
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
Chapter_002.ppt
This document discusses blood banking reagents used in immunohematology laboratories. It describes the basic principles of testing, sources of antigen and antibody, and routine tests like ABO typing and antibody screening. The document outlines the four main categories of reagents - red blood cells, antisera, antiglobulin reagents, and potentiators. It also discusses quality control of reagents and different testing methods including tube, gel, and solid-phase techniques.
Bioclonetics summary presentation~july 2016
BioClonetics has created proprietary cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus and diphtheria.
Cybele final presentation
Cybele is developing a Huntington's disease cell model using induced pluripotent stem cells to enable drug discovery. The team aims to create affected medium spiny neurons in vitro that can be used by academic researchers and pharmaceutical companies to identify potential drug targets and test compounds. Cybele is exploring commercializing purified cell populations for research or providing screening services using their cell model with partners. The company's goal is to accelerate Huntington's disease drug development and reduce costs by enabling earlier testing and failure of non-viable compounds.
Accelerating the translation of medical research - 27 June
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Haro Pharmaceutical I-Corps@NIH 121014
This document summarizes meetings and interviews conducted by HaRo Pharmaceutical regarding development of a new drug to treat high-risk neuroblastoma. It discusses key activities like lead optimization, animal modeling, and clinical trials. Experts noted the importance of disease-relevant models and primary cell-based assays to generate convincing data. Clinical partners could support an IND application and initial trials. While the drug may have multiple indications, neuroblastoma requires more institutional support and approval from key opinion leaders. The document outlines HaRo's potential development path and identifies resources and partners needed at each stage.
Inglis Preprints in Biology and Medicine
This presentation was provided by John Inglis of Cold Spring Harbor Laboratory during the NISO virtual conference, The Preprint: Integrating the Form into the Scholarly Ecosystem, held on February 14, 2018.
sdAb Screening Services
Thanks to a longstanding presence in the market of sdAb development and our well-established screening platform, Creative Biolabs is the right partner to navigate the sdAb screening challenges. Focused on the field of sdAb discovery and development, we will use our skills to offer innovative and sophisticated sdAb screening services tailored to our customer's exact needs.
Lisa_Grimm
Lisa Grimm has over 20 years of experience developing, optimizing, and validating cell-based, immuno, and coagulation assays across various therapeutic areas including immunology, oncology, and haemostasis. She has worked at several contract research organizations and pharmaceutical companies developing assays to evaluate drug candidates and biomarkers. Currently, she is a research scientist at Tandem Labs developing and validating immunoassays including ADA and neutralizing antibody assays under GLP regulations to screen pre-clinical and clinical samples.
ACMG-Based Variant Classification with VSClinical
Golden Helix is a global bioinformatics company founded in 1998 that provides software for variant annotation, filtering, and interpretation. Their flagship products are VarSeq Suite and VSClinical. VarSeq Suite allows for powerful variant filtering and annotation using curated public databases and premium annotations. VSClinical streamlines variant classification using American College of Medical Genetics and Genomics guidelines through a four-phased workflow involving variant filtering, evidence assessment, classification, and reporting. It provides consistent results and reduces learning curves for users. Golden Helix has over 400 customers globally and their software is cited in thousands of peer-reviewed publications.
Antimicrobial Stewardship
This presentation discusses antimicrobial stewardship and the challenges of implementing stewardship programs globally. It notes the lack of infectious disease physicians and pharmacists in some countries. Effective stewardship requires a multidisciplinary team approach and overcoming barriers like lack of funding, open antibiotic access, and cultural resistance to change. The presentation highlights strategies that have worked in various settings, including technology solutions, empowering patients, identifying high-risk patients, and education programs. Measuring outcomes like reduced length of stay and improved patient outcomes can demonstrate the impact of stewardship.
SLAS Screen Design and Assay Technology SIG: SLAS2013 Presentation
SLAS Screen Design and Assay Technology SIG: SLAS2013 PresentationSLAS (Society for Laboratory Automation and Screening)
This file includes the SLAS2013 presentations of Paul A. Johnston of University of Pittsburgh; Douglas Auld of Novartis Institutes for Biomedical Research; and Lisa Minor of In Vitro Strategies, LLC.Toxikon by kevin breesch
Toxikon is a contract research organization providing analytical, preclinical, and toxicology services. It has over 30 years of experience working with medical device, pharmaceutical, and biotech clients. The company has laboratories in the US and Belgium that are ISO 17025 accredited and GMP/GLP compliant. It offers a range of proof-of-concept, preclinical toxicology, and analytical chemistry services to support drug and device development from research through regulatory approval.
Discovering New Innovations in Oncology
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
BASIC OF IHC BY GEORGE YEABYO-ETHIOPIA.pptx
This power point presentation helps to understand the basics of Immunohistochemistry (IHC) and use as an intriduction of it.
Lisa_Grimm
Lisa Grimm has over 15 years of experience developing, optimizing, and validating various immunoassays, cell-based assays, and coagulation assays. She has worked in immunology, oncology, haemostasis, and biologics at several pharmaceutical companies. Currently she is a research scientist at Tandem Labs developing and validating immunoassays like ADA and neutralizing antibody assays under GLP regulations.
PBIO Investor Presentation
Pressure BioSciences is presenting their pressure cycling technology instruments and consumables. Their flagship product is the Barocycler 2320EXTREME instrument, which uses high pressure cycling to prepare biological samples for analysis. They have over 270 PCT systems installed worldwide and publications highlighting the advantages of PCT in biopharma sample preparation from discovery to clinical use. The company is poised for growth with their exclusive marketing agreement with SCIEX, expanded sales team, and focus on the multi-billion dollar biopharma market.
Similar to Presentation of Andrew Chalmers in 1st International Antibody Validation Forum 2014 (20)
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
Antibody Discovery by Single B Cell Screening on Beacon®
Antibody Discovery by Single B Cell Screening on Beacon®
Accelerating the translation of medical research - 27 June
Accelerating the translation of medical research - 27 June
SLAS Screen Design and Assay Technology SIG: SLAS2013 Presentation
SLAS Screen Design and Assay Technology SIG: SLAS2013 Presentation
More from St John's Laboratory Ltd
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.
Anti-Smo antibody (STJ95710): http://www.stjohnslabs.com/smo-antibody-p-94371?filter_name=STJ95710
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)St John's Laboratory Ltd
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling . Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity). Has transcriptional activation and repression activity . Mediates glucocorticoid-induced apoptosis . Promotes accurate chromosome segregation during mitosis . May act as a tumor suppressor . May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity). / Isoform Beta: Acts as a dominant negative inhibitor of isoform Alpha . Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed.
Join our Antibody Validation Project: http://www.stjohnslabs.com/services/antibody-validation
Anti glucocorticoid receptor antibody (STJ97101):
http://www.stjohnslabs.com/glucocorticoid-receptor-antibody-p-98736?filter_name=STJ97101Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Binds to F-actin and exhibits pH-sensitive F-actin depolymerizing activity. Regulates actin cytoskeleton dynamics. Important for normal progress through mitosis and normal cytokinesis. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required for the up-regulation of atypical chemokine receptor ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation.
Anti-Phospho-Cofilin (S3) -http://www.stjohnslabs.com/phospho-cofilin-s3-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Scientist of the Month - May Byron Baron
This June, Dr. Byron Baron from the University of Malta, Malta, is our Scientist of the Month! He's shared with us his research highlights, his current projects and some comments on the biotechnology industry.
Want to be our Scientist of the Month? Contact info@stjohnslabs.com
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex.
Anti-WAVE2 -http://www.stjohnslabs.com/wave2-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Implicated in synaptic vesicle endocytosis. May recruit other proteins to membranes with high curvature.
Brain, mostly in frontal cortex. Expressed at high level in fetal cerebellum.
Anti-Endophilin I -http://www.stjohnslabs.com/endophilin-i-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. TUBB3 plays a critical role in proper axon guidance and mantainance.
Anti-β-tubulin -http://www.stjohnslabs.com/b-tubulin-antibody-p-98672
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...St John's Laboratory Ltd
Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. / Strict requirement for Asp at position P1 and has a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp-|-(Gly/Ser/Ala). / Inhibited by the effector protein NleF that is produced by pathogenic E.coli; this inhibits apoptosis.
Anti-Caspase-8-http://www.stjohnslabs.com/caspase-8-antibody-p-99045
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...St John's Laboratory Ltd
Tubulin is the major constituent of microtubules. The gamma chain is found at microtubule organizing centers (MTOC) such as the spindle poles or the centrosome. Pericentriolar matrix component that regulates alpha/beta chain minus-end nucleation, centrosome duplication and spindle formation.
Anti-Gamma Tubulin-http://www.stjohnslabs.com/gamma-tubulin-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validation
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...St John's Laboratory Ltd
This document describes immunohistochemistry protocols for validating an anti-epsilon tubulin antibody in paraffin-embedded tissue samples of human liver, rat lung, kidney, spleen, and mouse lung. The protocol involves tissue processing, antigen retrieval, blocking, primary and secondary antibody incubation, DAB staining, hematoxylin counterstaining, dehydration, clearing, and visualization under a microscope. Validation results showed specific staining of epsilon tubulin in the tissue samples.Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...St John's Laboratory Ltd
Produces green light with a wavelength of 562 nm. / Photinus luciferin + O2 + ATP = oxidized Photinus luciferin + CO2 + AMP + diphosphate + light.
Anti-Luciferase -http://www.stjohnslabs.com/luciferase-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...St John's Laboratory Ltd
Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes) . Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation .
Anti-LC3A-http://www.stjohnslabs.com/lc3a-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...St John's Laboratory Ltd
Multifunctional transcription factor in ER stress response. Plays an essential role in the response to a wide variety of cell stresses and induces cell cycle arrest and apoptosis in response to ER stress. Plays a dual role both as an inhibitor of CCAAT/enhancer-binding protein (C/EBP) function and as an activator of other genes. Acts as a dominant-negative regulator of C/EBP-induced transcription: dimerizes with members of the C/EBP family, impairs their association with C/EBP binding sites in the promoter regions, and inhibits the expression of C/EBP regulated genes. Positively regulates the transcription of TRIB3, IL6, IL8, IL23, TNFRSF10B/DR5, PPP1R15A/GADD34, BBC3/PUMA, BCL2L11/BIM and ERO1L. Negatively regulates; expression of BCL2 and MYOD1, ATF4-dependent transcriptional activation of asparagine synthetase (ASNS), CEBPA-dependent transcriptional activation of hepcidin (HAMP) and CEBPB-mediated expression of peroxisome proliferator-activated receptor gamma (PPARG).
Anti-CHOP-http://www.stjohnslabs.com/chop-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...St John's Laboratory Ltd
Pseudokinase that plays a key role in TNF-induced necroptosis, a programmed cell death process. Activated following phosphorylation by RIPK3, leading to homotrimerization, localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage. Does not have protein kinase activity.
Anti-phospho-MLKL (S358)-http://www.stjohnslabs.com/phospho-mlkl-s358-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...St John's Laboratory Ltd
This document summarizes the immunohistochemistry protocol used to analyze ERK1 protein expression in human uterus tissue samples. Key steps included: antigen retrieval using citric acid; blocking of endogenous peroxidase; primary antibody incubation with anti-ERK1 antibody overnight at 4°C; secondary antibody incubation at room temperature for 30 minutes; DAB staining to visualize positive results; hematoxylin counterstaining; dehydration and clearing of slides; and visualization under a microscope. The protocol validated that the anti-ERK1 antibody specifically labeled ERK1 protein in human uterus tissue as expected.Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...St John's Laboratory Ltd
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation.
Anti-PDGFRα-http://www.stjohnslabs.com/pdgfra-antibody-2
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...St John's Laboratory Ltd
Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis. / Strict requirement for an Asp residue at position P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-. / Specifically inhibited by the cowpox virus Crma protein.
Anti-Caspase-1-http://www.stjohnslabs.com/caspase-1-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...St John's Laboratory Ltd
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu2+-mediated low-density lipoprotein oxidation.
Anti-Amyloid-β-http://www.stjohnslabs.com/amyloid-v-antibody
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...St John's Laboratory Ltd
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release .
Anti-Bcl-2-http://www.stjohnslabs.com/bcl-2-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationImmunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...St John's Laboratory Ltd
Alpha-actin-2 also known as actin, aortic smooth muscle or alpha smooth muscle actin (α-SMA, SMactin, alpha-SM-actin, ASMA) is a protein that in humans is encoded by the ACTA2 gene located on 10q22-q24. Actin alpha 2, the human aortic smooth muscle actin gene, is one of six different actin isoforms which have been identified. Actins are highly conserved proteins that are involved in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile apparatus. Alpha-smooth muscle actin (α-SMA) is commonly used as a marker of myofibroblast formation.
Anti-α-SMA -http://www.stjohnslabs.com/a-sma-antibody-1
Join our Antibody Validation Project - http://www.stjohnslabs.com/services/antibody-validationMore from St John's Laboratory Ltd (20)
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
Immunohistochemistry Customer Review Anti-Smo antibody (STJ95710)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti Glucocorticoid Receptor antibody (STJ97101)
Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Western Blot Customer Review Anti-Phospho-Cofilin (S3) Antibody (STJ90230)
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Western Blot Customer Review Anti-WAVE2 Antibody (STJ96263)
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Western Blot Customer Review Anti-Endophilin I Antibody (STJ92924)
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Western Blot Customer Review Anti-β-tubulin Antibody (STJ97037)
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-8 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Gamma Tubulin Antibo...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Epsilon Tubulin Anti...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-Luciferase Antibody ...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-LC3A Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-CHOP Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-phospho-MLKL (S358) ...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-ERK1 Antibody (STJ97...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-PDGFRα Antibody (STJ...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Caspase-1 Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Amyloid-β Antibody (...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-Bcl-2 Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Immunohistochemistry Antibody Validation Report for Anti-α-SMA Antibody (STJ9...
Recently uploaded
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Centrifugation is a powerful technique used in laboratories to separate components of a heterogeneous mixture based on their density. This process utilizes centrifugal force to rapidly spin samples, causing denser particles to migrate outward more quickly than lighter ones. As a result, distinct layers form within the sample tube, allowing for easy isolation and purification of target substances.
Quality assurance B.pharm 6th semester BP606T UNIT 5
Warehousing
Good warehousing practices
Material management
Signatures of wave erosion in Titan’s coasts
The shorelines of Titan’s hydrocarbon seas trace flooded erosional landforms such as river valleys; however, it isunclear whether coastal erosion has subsequently altered these shorelines. Spacecraft observations and theo-retical models suggest that wind may cause waves to form on Titan’s seas, potentially driving coastal erosion,but the observational evidence of waves is indirect, and the processes affecting shoreline evolution on Titanremain unknown. No widely accepted framework exists for using shoreline morphology to quantitatively dis-cern coastal erosion mechanisms, even on Earth, where the dominant mechanisms are known. We combinelandscape evolution models with measurements of shoreline shape on Earth to characterize how differentcoastal erosion mechanisms affect shoreline morphology. Applying this framework to Titan, we find that theshorelines of Titan’s seas are most consistent with flooded landscapes that subsequently have been eroded bywaves, rather than a uniform erosional process or no coastal erosion, particularly if wave growth saturates atfetch lengths of tens of kilometers.
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
We present the JWST discovery of SN 2023adsy, a transient object located in a host galaxy JADES-GS
+
53.13485
−
27.82088
with a host spectroscopic redshift of
2.903
±
0.007
. The transient was identified in deep James Webb Space Telescope (JWST)/NIRCam imaging from the JWST Advanced Deep Extragalactic Survey (JADES) program. Photometric and spectroscopic followup with NIRCam and NIRSpec, respectively, confirm the redshift and yield UV-NIR light-curve, NIR color, and spectroscopic information all consistent with a Type Ia classification. Despite its classification as a likely SN Ia, SN 2023adsy is both fairly red (
�
(
�
−
�
)
∼
0.9
) despite a host galaxy with low-extinction and has a high Ca II velocity (
19
,
000
±
2
,
000
km/s) compared to the general population of SNe Ia. While these characteristics are consistent with some Ca-rich SNe Ia, particularly SN 2016hnk, SN 2023adsy is intrinsically brighter than the low-
�
Ca-rich population. Although such an object is too red for any low-
�
cosmological sample, we apply a fiducial standardization approach to SN 2023adsy and find that the SN 2023adsy luminosity distance measurement is in excellent agreement (
≲
1
�
) with
Λ
CDM. Therefore unlike low-
�
Ca-rich SNe Ia, SN 2023adsy is standardizable and gives no indication that SN Ia standardized luminosities change significantly with redshift. A larger sample of distant SNe Ia is required to determine if SN Ia population characteristics at high-
�
truly diverge from their low-
�
counterparts, and to confirm that standardized luminosities nevertheless remain constant with redshift.
Male reproduction physiology by Suyash Garg .pptx
Physiology of Male reproduction.
Video mentioned at page no. 23 as summary for better understanding
Pests of Storage_Identification_Dr.UPR.pdf
InIndia-post-harvestlosses-unscientificstorage,insects,rodents,micro-organismsetc.,accountforabout10percentoftotalfoodgrains
Graininfestation
Directdamage
Indirectly
•theexuviae,skin,deadinsects
•theirexcretawhichmakefoodunfitforhumanconsumption
About600speciesofinsectshavebeenassociatedwithstoredgrainproducts
100speciesofinsectpestsofstoredproductscauseeconomiclosses
fermented food science of sauerkraut.pptx
This ppt contains the production of a fermented food name - sauerkraut
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...ABHISHEK SONI NIMT INSTITUTE OF MEDICAL AND PARAMEDCIAL SCIENCES , GOVT PG COLLEGE NOIDA
Microbial interaction
Microorganisms interacts with each other and can be physically associated with another organisms in a variety of ways.
One organism can be located on the surface of another organism as an ectobiont or located within another organism as endobiont.
Microbial interaction may be positive such as mutualism, proto-cooperation, commensalism or may be negative such as parasitism, predation or competition
Types of microbial interaction
Positive interaction: mutualism, proto-cooperation, commensalism
Negative interaction: Ammensalism (antagonism), parasitism, predation, competition
I. Mutualism:
It is defined as the relationship in which each organism in interaction gets benefits from association. It is an obligatory relationship in which mutualist and host are metabolically dependent on each other.
Mutualistic relationship is very specific where one member of association cannot be replaced by another species.
Mutualism require close physical contact between interacting organisms.
Relationship of mutualism allows organisms to exist in habitat that could not occupied by either species alone.
Mutualistic relationship between organisms allows them to act as a single organism.
Examples of mutualism:
i. Lichens:
Lichens are excellent example of mutualism.
They are the association of specific fungi and certain genus of algae. In lichen, fungal partner is called mycobiont and algal partner is called
II. Syntrophism:
It is an association in which the growth of one organism either depends on or improved by the substrate provided by another organism.
In syntrophism both organism in association gets benefits.
Compound A
Utilized by population 1
Compound B
Utilized by population 2
Compound C
utilized by both Population 1+2
Products
In this theoretical example of syntrophism, population 1 is able to utilize and metabolize compound A, forming compound B but cannot metabolize beyond compound B without co-operation of population 2. Population 2is unable to utilize compound A but it can metabolize compound B forming compound C. Then both population 1 and 2 are able to carry out metabolic reaction which leads to formation of end product that neither population could produce alone.
Examples of syntrophism:
i. Methanogenic ecosystem in sludge digester
Methane produced by methanogenic bacteria depends upon interspecies hydrogen transfer by other fermentative bacteria.
Anaerobic fermentative bacteria generate CO2 and H2 utilizing carbohydrates which is then utilized by methanogenic bacteria (Methanobacter) to produce methane.
ii. Lactobacillus arobinosus and Enterococcus faecalis:
In the minimal media, Lactobacillus arobinosus and Enterococcus faecalis are able to grow together but not alone.
The synergistic relationship between E. faecalis and L. arobinosus occurs in which E. faecalis require folic acid
Post translation modification by Suyash Garg
overview of PTM helps to the students who wants to clear their basics about it.
Reaching the age of Adolescence- Class 8
This is a presentation on understanding the age of adolescence.
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
Ozturkcan, S., Berndt, A., & Angelakis, A. (2024). Mending clothing to support sustainable fashion. Presented at the 31st Annual Conference by the Consortium for International Marketing Research (CIMaR), 10-13 Jun 2024, University of Gävle, Sweden.
Embracing Deep Variability For Reproducibility and Replicability
Embracing Deep Variability For Reproducibility and ReplicabilityUniversity of Rennes, INSA Rennes, Inria/IRISA, CNRS
Embracing Deep Variability For Reproducibility and Replicability
Abstract: Reproducibility (aka determinism in some cases) constitutes a fundamental aspect in various fields of computer science, such as floating-point computations in numerical analysis and simulation, concurrency models in parallelism, reproducible builds for third parties integration and packaging, and containerization for execution environments. These concepts, while pervasive across diverse concerns, often exhibit intricate inter-dependencies, making it challenging to achieve a comprehensive understanding. In this short and vision paper we delve into the application of software engineering techniques, specifically variability management, to systematically identify and explicit points of variability that may give rise to reproducibility issues (eg language, libraries, compiler, virtual machine, OS, environment variables, etc). The primary objectives are: i) gaining insights into the variability layers and their possible interactions, ii) capturing and documenting configurations for the sake of reproducibility, and iii) exploring diverse configurations to replicate, and hence validate and ensure the robustness of results. By adopting these methodologies, we aim to address the complexities associated with reproducibility and replicability in modern software systems and environments, facilitating a more comprehensive and nuanced perspective on these critical aspects.
https://hal.science/hal-04582287
Methods of grain storage Structures in India.pdf
•Post-harvestlossesaccountforabout10%oftotalfoodgrainsduetounscientificstorage,insects,rodents,micro-organismsetc.,
•Totalfoodgrainproductioninindiais311milliontonnesandstorageis145mt.InIndia,annualstoragelosseshavebeenestimated14mtworthofRs.7,000croreinwhichinsectsaloneaccountfornearlyRs.1,300crores.
•InIndiaoutofthetotalproduction,about30%ismarketablesurplus
•Remaining70%isretainedandstoredbyfarmersforconsumption,seed,feed.Hence,growerneedstoragefacilitytoholdaportionofproducetosellwhenthemarketingpriceisfavourable
•TradersandCo-operativesatmarketcentresneedstoragestructurestoholdgrainswhenthetransportfacilityisinadequate
Recently uploaded (20)
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
TOPIC OF DISCUSSION: CENTRIFUGATION SLIDESHARE.pptx
Quality assurance B.pharm 6th semester BP606T UNIT 5
Quality assurance B.pharm 6th semester BP606T UNIT 5
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
MICROBIAL INTERACTION PPT/ MICROBIAL INTERACTION AND THEIR TYPES // PLANT MIC...
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
Mending Clothing to Support Sustainable Fashion_CIMaR 2024.pdf
Embracing Deep Variability For Reproducibility and Replicability
Embracing Deep Variability For Reproducibility and Replicability
Nutaceuticsls herbal drug technology CVS, cancer.pptx
Nutaceuticsls herbal drug technology CVS, cancer.pptx
Presentation of Andrew Chalmers in 1st International Antibody Validation Forum 2014
- 1. CiteAb and Antibody Validation 1st International Antibody Validation Forum Andrew Chalmers @Chalmers_AD October 2014
- 2. Approaches to antibody validation • There are multiple approaches to antibody validation. • Ranging from simple controls to high throughput approaches. b-Tubulin 72kD- 52kD- 42kD- 34kD-RASSF7 control RASSF7 KD b-Tubulin Recino et al Biochem J 2010
- 3. Application specific antibodies • Antibodies may work in one application but not another. Anti-GFP antibodies which are suitable for IF, FACS and ChIP but notWestern Blotting Sanchez et al Monoclonal Antib. Immunodiagn. Immunother. (2014)
- 4. Species cross reactivity ? ?
- 5. Antibody validation is an ongoing process Or a never ending struggle! • Some suppliers do more validation than others. • No supplier can test an antibody for every application with every tissue from every species! • When choosing an antibody it is important to look for independent validation.
- 6. Types of third party validation • Contract research organisations • Antibody reviews • Peer reviewed scientific publications
- 7. CiteAb: The Antibody Search Engine • Ranked by citations • Independent and free to list
- 9. CiteAb: An antibody page
- 10. CiteAb: A publication page
- 11. CiteAb: How do we keep going? • Enhanced profiles • Custom antibody services listing • Providing citations • Antibody market data Top Institutions for using neuroscience antibodies How many antibodies are there to each human protein Swiss-Prot Number Number of Institution Share of antibodies Company X’s share in the USA citations Protein W 0 University College London 17.66% University of Cambridge 11.90% Protein X 0 University of Oxford 10.15% Protein Y 1000 University of Edinburgh 7.32% Protein Z 100 King's College London 7.32%
- 12. It seems useful! Thousands of returning users Users from 160 countries A high proportion link to antibody companies Universities Bath University of London Cambridge Yale Harvard Pharmaceutical companies Bristol-Myers Squibb GSK AstraZeneca Pfizer Novartis Eli Lilly Research Institutes NIH MIT Korea advanced institute of science and technology Indian institute of science education and research Institute of Cancer research. Karolinska Institute
- 13. Once you have chosen your antibody • You still need to validate it in your own lab! • Cite the antibody properly when you publish your data
- 14. Acknowledgements • CiteAb (@citeab) Matt Helsby, Dave Kelly, Adam Pope, Katrina Kelly, Paul Leader and Mark Farmer. • University of Bath (@uniofbath) Biology and Biochemistry, RDSO (especially Graham Fisher) and the Legal Services Team.
Editor's Notes
- Including not for profits like DSHB